Vaccines for Japanese Encephalitis
The table below lists products with a valid marketing authorisation. The list does not provide information as to whether the products are also available on the market. The information provided here is supplied without liability for errors or omissions. For information which is legally binding, please refer to the relevant marketing authorisation certificate. Official publications of the Paul-Ehrlich-Institut appear in the Bundesanzeiger (Federal Gazette).
Where the European Medicines Agency (EMA) provides further information, you will find a link called EPAR.
If SPCs, package leaflets or public assessment reports are available in PharmNet, the gateway for information on medicinal products of the Federal Republic of Germany and the Länder (German Federal states), these are linked with the term PharmNet.
The most recent publication included in the section "Medicinal Products" is Federal Gazette publication No 438 (BAnz AT 13.10.2017 B6).
Explanation on age
(Relationship between year of life and age as indicated in the Summary of Product Characteristics (SmPC) and in the package leaflet) Examples: As from the 4th year means after the 36th month of a child’s life is completed (the completed 3rd year), i.e. in the 4th year, a child is three years of age. If the SmPC contains the indications "for infants and young children", the table below contains the recommended age stated in the vaccination calendar by the STIKO (Ständige Impfkommission, German Standing Vaccination Committee). The table always indicated the age of a child).
Kombi: combined vaccine
Mono: monovalent vaccine
|Name||Product Characteristics||Marketing Authorisation Holder||Kind of Vaccine||License Number||License Date||Further Information|
Japanischer-Enzephalitis-Virus Impfstoff (inaktiviert, adsorbiert)
Verwendung ab einem Lebensalter von 2 Monaten
|Valneva Austria GmbH||Mono||EU/1/08/501/001-002||31.03.2009|